Skyhawk Therapeutics

Skyhawk Therapeutics is a clinical-stage biotechnology company focused on developing novel small molecule therapies that modify RNA expression. Their mission is to revolutionize disease treatment by tackling intractable diseases that are currently considered "undruggable" using traditional protein-targeting methods. Skyhawk's unique platform, SKYSTAR®, integrates four distinct and complementary technologies with machine learning models to accelerate the development of RNA-targeting small molecule drug candidates across a range of targets. They have a broad portfolio of drug candidates in their pipeline, including programs for neurodegenerative diseases, oncology, neuromuscular disorders, fibrotic diseases, and other disease types.

Skyhawk has secured significant funding through partnerships with major pharmaceutical companies, including BMS, Biogen, Genentech, Ipsen, Merck, Sanofi, Takeda, and Vertex. These collaborations have contributed to Skyhawk's rapid growth and development, and they continue to invest in their proprietary platform to drive the discovery and development of novel RNA splicing modulators. Their first program, SKY-0515, targeting Huntington's disease, is in clinical trials and has demonstrated a 72% reduction in HTT mRNA in its Phase 1 Healthy Volunteer MAD study. They are actively advancing their internal pipeline with the goal of bringing novel treatments to patients suffering from a variety of debilitating diseases.

Skyhawk Therapeutics is a clinical-stage biotechnology company dedicated to revolutionizing disease treatment by developing small molecule therapeutics that modify RNA expression. Their mission focuses on addressing RNA mis-expression, which is known to cause a wide range of diseases, including orphan and neurological conditions, as well as major cancers. They aim to provide breakthrough treatments for patients by harnessing the power of the immune system and targeting historically "undruggable" conditions.

Skyhawk Therapeutics fosters a culture of innovation and collaboration, driven by a shared commitment to developing breakthrough treatments for patients with intractable diseases. The company values scientific excellence, diversity, and a passion for making a difference in the lives of those affected by challenging medical conditions.